Back to Press-Releases

DIA Appoints Dr. Tong-Yan Wang as Senior Vice President and Managing Director, Greater China

DIA, founded as the Drug Information Association, has named Tong-Yan Wang, PhD, as Senior Vice President and Managing Director, Greater China. In this capacity, Wang will be tasked with leading the regional strategic efforts of DIA, which provides the largest global, neutral, multidisciplinary forum for life science professionals to engage with key stakeholders and each other, as well as continuing the evolution of the organization’s thought leadership and knowledge platforms in Asia and beyond.

Prior to joining DIA, Wang served as CEO of Sanpower Group, where she played a pivotal role in the build-up of its healthcare business. With more than 20 years of experience in the pharmaceutical industry in business leadership, marketing, and product development roles, Wang served as Head of Market Access and Government Affairs for China and began her career as a professor at Xian Medical University. She holds a PhD in Strategy Management from ISCTE, Portugal, an MBA from Xian Jiao Tong University, and a Bachelor of Medical Science degree from Xian Medical University.

“The challenges facing public health are global, and Dr. Wang is excellently poised to engage leaders at all levels and disciplines in areas of emerging resources, patients, and regulatory environments,” said Barbara Lopez Kunz, Global Chief Executive, DIA. “Dr. Wang possesses keen intelligence and strategic experience in a variety of international life science arenas, and we look forward to working with her to help our members and stakeholders expand and accelerate access to life-changing therapies in China and other important geographies.”

“I am looking forward to the possibilities of tomorrow – for DIA, for regulator / industry collaboration, for international sharing, but ultimately, for patients,” said Wang. “This is an important moment in healthcare – whether it’s clinical development pathways for rapid approval of innovative therapies and devices in China or adoption and harmonization of global pharmacovigilance and drug safety reporting standards worldwide, we stand on the precipice of significant breakthroughs, and I’m so proud to be part of an organization that believes so strongly in this effort.”